NEW YORK, NY--(Marketwire - July 25, 2012) -
Immunovative, Inc. ("IMUN") (OTCBB: IMUN
) announces the appointment of Professor Emmanuel Katsanis, MD as Chief Medical Officer, Medical Monitor and Chairman of the Scientific Advisory Board of Immunovative Therapies, Ltd. ("ITL"). As the Chief Medical Officer, Dr. Katsanis will provide medical guidance, strategic advice and oversight of ITL's worldwide clinical development programs, including selection of target indications, protocol design and design of immunological monitoring end-points. As Medical Monitor, Dr. Katsanis will assist in assuring for the safety of subjects in clinical trials sponsored by ITL and in review and analysis of any immune-related adverse events encountered during clinical development. As Chairman of the Scientific Advisory Board, Dr. Katsanis will recruit and lead a world-class team of medical researchers and immunological researchers that will oversee and advise ITL regarding internal research and development, external collaborative research and clinical development programs.
Dr. Katsanis is a board certified pediatric hematologist/oncologist and author of over 80 peer-reviewed articles in cancer, immunology and immunotherapy. He is professor of pediatrics, medicine, pathology and immunobiology at the University of Arizona College of Medicine in Tucson and is the Director of the Blood and Bone Marrow Transplant Program and the Director of the MD-PhD Program. Dr. Katsanis holds the Louise Thomas Endowed Chair in Pediatric Cancer Research at the Steele Children's Research Center, and heads the Division of Pediatric Hematology/Oncology. Dr. Katsanis is the principal inventor of Chaperone Rich Cell Lysate ("CRCL") technology, which was in-licensed by ITL from the University of Arizona in 2009 and serves as the basis of ITL's AlloVax™ experimental cancer vaccine product. Dr. Katsanis serves as a charter member of the NIH/NCI Clinical Oncology Study Section responsible for reviewing immunotherapy grant proposals for US government funding.
Dr. Katsanis stated: "I believe that ITL technology represents a major breakthrough in the field of immunotherapy. I am excited for the opportunity to join ITL and assist in the translation of its novel immunotherapy products to clinical practice. Since the licensing of our CRCL product to ITL, I have had the opportunity to observe how the ITL team efficiently translated our idea into a product that can now be consistently produced under good manufacturing practices. My laboratory has also been able to repeat and expand upon the pre-clinical animal work originally published by ITL, confirming the great potential of the ITL technology. I believe my background and expertise will be able to assist ITL in bringing this technology forward in clinical trials and eventually to commercialization. I look forward with enthusiasm to the further development of this novel immunotherapy approach."
Dr. Michael Har-Noy, CEO of Immunovative Therapies, Ltd., stated: "We are very pleased that our technology and product development has been able to attract such a noted and established medical scientist. Dr. Katsanis is a world-renowned specialist in immunotherapy and will perform a critical role in developing strategy for the design, conduct, analysis and reporting of our planned pre-clinical and clinical development programs."
About Immunovative, Inc.:
About Immunovative, Inc.: On December 15, 2011, Immunovative, Inc. ("IMUN") signed an exclusive License Agreement (the "License Agreement") with Immunovative Therapies, Ltd ("ITL"). Under the terms of the License Agreement, IMUN has been granted an exclusive, worldwide license to commercialize any products covered under ITL's current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products including.
About Immunovative Therapies, Ltd.:
Immunovative Therapies, Ltd. is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israel Office of the Chief Scientist. Immunovative is a graduate of the Misgav Venture Accelerator, a member of the world-renowned Israel technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. Immunovative Therapies Ltd specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for treatment of cancer and infectious disease. Please visit Immunovative's website at: www.immunovative.co.il
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on IMUN's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which IMUN has little or no control. Such forward-looking statements are made only as of the date of this release, and IMUN assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by IMUN with the Securities and Exchange Commission.